-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Melpida in Paraplegia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Melpida in Paraplegia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Melpida in Paraplegia Drug Details: Melpida is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Laryngeal Cancer Drug Details: Ruxolitinib (INCB18424, Jakafi,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AdAPT-001 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AdAPT-001 in Solid Tumor Drug Details: AdAPT-001 is under development for the treatment of malignant solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Conestat Alfa in Contrast Induced Nephropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Conestat Alfa in Contrast Induced Nephropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Conestat Alfa in Contrast Induced Nephropathy Drug Details: Conestat alfa...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Conestat Alfa in Delayed Graft Function (DGF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Conestat Alfa in Delayed Graft Function (DGF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Conestat Alfa in Delayed Graft Function (DGF) Drug Details:...
-
Product Insights
Vulvar Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vulvar Cancer - Drugs In Development, 2023’, provides an overview of the Vulvar Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vulvar Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vaginal Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Vaginal Cancer - Drugs In Development, 2023’, provides an overview of the Vaginal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vaginal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Penile Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Penile Cancer - Drugs In Development, 2023’, provides an overview of the Penile Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Penile Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Cervical Intraepithelial Neoplasia (CIN) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) - Drugs In Development, 2023’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...